Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Another Elagolix Study Supports AbbVie's NDA, But Which Dose?

This article was originally published in Scrip

Executive Summary

A second positive Phase III clinical trial for AbbVie Inc.'s elagolix in the treatment of endometriosis pain in premenopausal women supports a new drug application (NDA) submission to the US FDA in 2017, but it's unknown whether both doses tested in the trials will be viable in the real world.


Related Content

Keeping Track: Thumbs Up For Abbvie and GSK; Thumbs Down For Insys
Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review
10 First Approvals To Look Out For In 2018
Keeping Track: A Burst of CRLs and BTDs, A Busy Week Of Submissions And Another Approval For Soliris
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
Neurocrine Blames Sub-Par Dosing For Ingrezza Study Failure





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts